either ccA (less aggressive) or ccB (more aggressive) molecular subtypes. Age-and sex-adjusted logistic regression models estimated associations between sarcopenia and molecular subtype separately for obese and non-obese patients. Statistical significance was regarded as a p-value of<0.05.
INTRODUCTION AND OBJECTIVES: Current standards of tumor assessment often do not provide a comprehensive evaluation for the optimal management of renal cancer patients. While genomic and epigenomic biomarkers have shown improvements in patient risk classification, the heterogeneity of renal tumors on imaging can confound assessment. The objective was to investigate the association of contrast-enhanced computed tomography (CECT)-based radiomics obtained from clinical imaging features with DNA-methylation (DNAm) features that predict aggressive clear cell renal carcinoma (ccRCC).
METHODS: In this IRB-approved retrospective study, 29 patients (15 aggressive and 14 non-aggressive) with pathologically confirmed ccRCC and a pre-operative multiphase CECT were identified. An abdominal radiologist supervised the segmentation of each tumor from a clinical, standard of care CT study on a dedicated workstation. We evaluated 6 different types of texture extraction techniques from every phase of the imaging study. Genome-wide DNAm profiles were generated from tumor tissue extracted from the same patients using the Infinium Methylation EPIC array. We correlated all 1495 radiomic features processed with 97 DNAm features selected based on their strength of separating non-aggressive from aggressive renal tumors and non-aggressive from normal kidney in 281 ccRCC from the Cancer Genome Atlas. We computed Pearson and Spearman correlations depending on data distribution, for all possible pairs of radiomics and DNAm features. The results were summarized within each of the 6 radiomics categories by the percent of correlation coefficients attaining nominal p<0.05 for each DNAm feature (suggestive of a positive signal) and presented in a heatmap (Figure 1) .
RESULTS: There were significant (p<0.05) correlations between the selected epigenetic features and the radiomics features. Gray-level difference method (GLDM) 2D and 3D were shown having a strong signal in the correlation with cg12697139 and cg16973527. In general, second-order statistical texture method: GLDM was seen to have the most correlation with selected epigenetic nodes.
CONCLUSIONS: To our knowledge, this is the first study to correlate epigenomic profiles with CECT based radiomics features of renal masses. We plan to validate the finding in a larger patient cohort study.
Source of Funding: Whittier Foundation

MP72-19 PLASMA GLYCOSAMINOGLYCAN SCORES IN RENAL CELL CARCINOMA
Kyle A. Blum*, New York City, NY; Francesco Gatto, Goteberg, Sweden; Mazyar Ghannat, Alejandro Sanchez, New York City, NY; Francesca Maccari, Fabio Galeotti, Modena, Italy; James Hsieh, St. Louis, MO; Nicola Volpi, Modena, Italy; A. Ari Hakimi, New York City, NY; Jens Nielsen, Goteberg, Sweden INTRODUCTION AND OBJECTIVES: Glycosaminoglycan (GAG) levels are measurably altered in the plasma of patients with clear cell renal cell carcinoma (ccRCC). GAG scores have been used to detect ccRCC in a cohort of patients with metastatic disease with 92.7% accuracy (Gatto et al, Cell Reports, 2016) . However, it is unknown if GAG scores can detect RCC in earlier stages or non-ccRCC histologies.
METHODS: In this retrospective study, pre-operative plasma GAG levels from 162 RCC patients were compared to 19 healthy controls between 5/2011-2/2014. GAG scores were generated using 19 pre-specified properties and measured using capillary electrophoresis with laser induced fluorescence. GAG profile differences in RCC versus healthy controls were assessed using unsupervised clustering methods. A discovery set of 68 RCC vs. 19 healthy samples were first analyzed to update the historical GAG score. The new GAG score accuracy in RCC detection versus healthy subjects was validated using the remaining 94 RCC samples. RESULTS: Median age was similar between RCC and healthy cohorts, 60 years (IQR: 52-67) vs. 55 years (IQR: 50-60), respectively. In the RCC cohort, 113 (70%) were ccRCC and 49 (30%) non-ccRCC. RCC stage included 86 (53%) pT1, 66 (41%) pT2-3, and 12 (7%) pT4. GAG profiles in RCC clustered separately from healthy volunteers ( Figure 1A ). In the first discovery set (n¼68), the GAG score distinguished RCC from healthy subjects with an AUC equal to 0.999, 94.7% specificity and 100% sensitivity at an optimal cut-off equal to 0.87 ( Figure 1B ). In the validation set (n¼94), the GAG score achieved an AUC equal to 0.994 (95% CI: 0.985 -1) and 95.7% sensitivity ( Figure  1B) . GAG scores did not correlate with age or gender. GAG scores were elevated in all RCC samples compared to normal controls, irrespective and uncorrelated to stage, grade or histology.
CONCLUSIONS: Plasma GAG scores are measurably elevated in RCC compared to healthy individuals. It was possible to detect RCC irrespective of stage or histology with 95.7% sensitivity. GAG scores did not correlate with pathologic stage, grade, or histology. These findings suggest that GAG alterations occur early in tumor formation but are likely independent of progression. These findings warrant prospective validation to assess the clinical utility of pre-operative GAG scores as biomarkers for RCC. Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e959 INTRODUCTION AND OBJECTIVES: Mitochondrial DNA (mtDNA) accumulates mutations at a 10-fold higher rate than nuclear DNA, owing to the lack of protective histones and limited capacity for DNA repair. It contains 13 coding genes involved in oxidative phosphorylation and a non-coding region, which includes a displacement loop (D-loop), regulating mtDNA replication. To examine the correlation between mtDNA mutations and postoperative recurrence in RCC, we focused on mutations in ND1, encoding NADH dehydrogenase subunit 1, as a coding gene representative and D-loop as a non-coding region representative.
METHODS: Clinicopathological data were collected from a total of 61 patients, who underwent radical surgery for localized RCC in 2010. The sequences of ND1 and D-loop (mtDNA) in RCC tissues were compared with the sequence data from corresponding non-cancerous renal tissues. Clinicopathological features included age, sex, histological subtype, pathological stage T (pT), nuclear grade, microvascular invasion (MVI), and mtDNA mutations. The associations of clinicopathological features with time to postoperative recurrence after curative surgery were evaluated by statistical analysis. RESULTS: Among the 61 patients, there were 47 male and 14 female patients with a median age of 62 (39-80) years. The median follow-up period was 66.5 (29-76) months. Of the 61 patients, 10 had recurrent RCC. Concerning pathological characteristics, there were 54 patients with clear cell RCC and 7 patients with non-clear cell RCC. Fifty-six patients had pT 1-2 tumors, and the others had pT 3-4 tumors. Fuhrman grading showed that 53 cases were grade I/II, and 8 cases were grade III/IV. MVI was observed in 13 patients. Among the 61 RCC cases, mtDNA gene sequencing revealed the existence of somatic mutations in 14 cases. The 5-year RFS rate was significantly low in patients with pT stage 3, Fuhrman grade III, MVI, and mtDNA gene mutations (Figure) . Multivariate analysis using these factors showed that mtDNA gene mutations constituted an independent risk factor for postoperative recurrence after curative surgery.
CONCLUSIONS: This is the first study to demonstrate a relationship between mtDNA mutations and postoperative recurrence in RCC. Mutations in the mitochondrial ND1 and D-loop may be useful biomarkers for the detection of postoperative recurrence in RCC. Although much work has focused on urinary and fecal incontinence (UI, FI) in people with spina bifida (SB), little is known about incontinence during sexual activity. Our aim was to evaluate the prevalence of and factors associated with UI and FI during sexual activity (UIS, FIS) among adults with SB.
METHODS: An international online survey of adults with SB was administered over 10 months (recruitment: SB clinics, SB organizations). Adults with a history of sexual activity (solo/partnered masturbation, intercourse) who reported ever having UIS or FIS were included. Baseline UI/FI was assessed in the last 4 weeks. Frequency and bother with UIS/FIS were evaluated (5-point Likert scale). Analysis involved non-parametric tests and logistic regression.
RESULTS: A total of 177 adults met inclusion criteria (median age: 36 years, 40.7% male), 95.5% had partnered sexual contact. Baseline UI in the last 4 weeks was reported by 66.7% and FI by 56.0% (p¼0.09). Twelve (6.8%) had a urostomy and 2 (1.1%) had a colostomy. Among adults without urinary diversion, UIS was more common than FIS (64.6% vs. 45.2%, p<0.001). For adults without a urostomy, UIS was more common among women than men (76.0% vs. 52.2%, p¼0.002) and those with baseline UI (79.0% vs. 48.7%, p¼0.02). UIS was not associated with age, shunt, ambulatory, or CIC status (p>¼0.32). On bivariate analysis, female gender and UI were independent predictors of UIS (p<¼0.001), indicating 4 different risk groups
